This article is based on a poster originally authored by Anne J Hout, Nikki Claassen, Ilse H Wolters, Johanna FB Pagano, and Karthikeyan Devaraju. Stable expression in gene therapies with transposons, ...

Nabsys 2.0, LLC ("Nabsys"), a pioneer in Electronic Genome Mapping (EGM), today announced the publication of a new preprint demonstrating that CRISPR/Cas9 can be used to customize how EGM identifies ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...

This article and associated images are based on a poster originally authored by Dhruv Sunil Choudhary and presented at ELRIG Drug Discovery 2025 in affiliation with the University of Westminster. This ...

Japanese researchers used CRISPR-Cas9 to remove the extra chromosome 21 from cells in a lab. It's a real breakthrough — but ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

Development of bespoke therapies has been a driving goal in medical research. This year, the announcement of the first patient treated with personalized CRISPR therapy, Baby KJ, highlights this ...

In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...